Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
KPRX 
Kiora Pharmaceuticals Inc (KPRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: KPRX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 0 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.25% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.04M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 2 | Beta -0.89 | 52 Weeks Range 1.76 - 4.18 | Updated Date 01/9/2026 |
52 Weeks Range 1.76 - 4.18 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.07% | Return on Equity (TTM) -32.58% |
Valuation
Trailing PE - | Forward PE 2.41 | Enterprise Value -10934989 | Price to Sales(TTM) 363.74 |
Enterprise Value -10934989 | Price to Sales(TTM) 363.74 | ||
Enterprise Value to Revenue 569.41 | Enterprise Value to EBITDA -1.03 | Shares Outstanding 3677935 | Shares Floating 3558300 |
Shares Outstanding 3677935 | Shares Floating 3558300 | ||
Percent Insiders 2.98 | Percent Institutions 19.58 |
Upturn AI SWOT
Kiora Pharmaceuticals Inc
Company Overview
History and Background
Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for inflammatory and fibrotic diseases. The company was founded with a vision to address unmet medical needs through innovative scientific approaches. Significant milestones include progression of its lead drug candidates through preclinical and early clinical development stages.
Core Business Areas
- Therapeutic Development: Kiora Pharmaceuticals Inc. is primarily engaged in the research and development of proprietary drug candidates targeting a range of inflammatory and fibrotic conditions. This involves extensive laboratory research, preclinical testing, and clinical trials.
Leadership and Structure
The leadership team of Kiora Pharmaceuticals Inc. comprises experienced professionals in drug development, clinical research, and business management. The organizational structure is typical for a biopharmaceutical company, with dedicated departments for R&D, clinical operations, regulatory affairs, and corporate functions.
Top Products and Market Share
Key Offerings
- Product Name 1: KIO-101 - A novel small molecule inhibitor targeting inflammatory pathways. Currently in early-stage clinical trials for fibrotic diseases. Competitors include companies developing JAK inhibitors and other targeted anti-inflammatory agents.
- Product Name 2: KIO-201 - A preclinical-stage drug candidate aimed at modulating fibrotic processes. Competitors are companies working on anti-fibrotic agents in various therapeutic areas.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. It is driven by innovation in disease understanding and therapeutic approaches, with a strong focus on unmet medical needs.
Positioning
Kiora Pharmaceuticals Inc. is positioned as an emerging player in the clinical-stage biopharmaceutical space, focusing on niche therapeutic areas with significant unmet needs. Its competitive advantage lies in its proprietary technology and scientific approach to drug discovery.
Total Addressable Market (TAM)
The TAM for inflammatory and fibrotic diseases is substantial, with market values in the tens of billions of dollars globally, driven by aging populations and increasing prevalence of chronic conditions. Kiora Pharmaceuticals Inc. is positioned to address a segment of this TAM with its specialized drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates with novel mechanisms of action.
- Experienced management and scientific team.
- Focus on therapeutic areas with significant unmet medical needs.
Weaknesses
- Limited financial resources typical of a clinical-stage company.
- Reliance on successful clinical trial outcomes.
- Lack of established commercialization infrastructure.
Opportunities
- Potential for strategic partnerships and collaborations.
- Growing market demand for treatments for inflammatory and fibrotic diseases.
- Advancements in genetic and molecular understanding of diseases.
Threats
- Failure of drug candidates in clinical trials.
- Intense competition from established pharmaceutical companies and other biotechs.
- Regulatory challenges and delays in drug approval.
Competitors and Market Share
Key Competitors
- Gilead Sciences Inc (GILD)
- AbbVie Inc (ABBV)
- Pfizer Inc (PFE)
- Bristol-Myers Squibb Company (BMY)
Competitive Landscape
Kiora Pharmaceuticals Inc. faces a highly competitive landscape populated by large, established pharmaceutical companies with extensive R&D capabilities and commercial infrastructure. Its advantage lies in its specialized focus and potentially first-in-class or best-in-class drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Kiora Pharmaceuticals Inc. is characterized by its progression through the drug development pipeline, from initial research to clinical trials. This is often accompanied by fundraising activities to support these stages.
Future Projections: Future growth projections are contingent on the successful development and regulatory approval of its drug candidates. Analyst estimates, if available, would focus on potential market penetration and revenue upon commercialization.
Recent Initiatives: Recent initiatives likely involve advancing its lead drug candidates into later-stage clinical trials, seeking strategic partnerships, and securing necessary funding to support ongoing R&D activities.
Summary
Kiora Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company with promising drug candidates for inflammatory and fibrotic diseases. Its strengths lie in its novel scientific approach and experienced team. However, it faces significant challenges due to its early stage, reliance on clinical success, and intense competition. Securing adequate funding and achieving positive clinical trial outcomes are crucial for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Industry reports
- Financial data providers
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute investment advice. Financial data and market share figures are estimates and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiora Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Encinitas, CA, United States | ||
IPO Launch date 2015-07-31 | President, CEO & Director Dr. Brian M. Strem Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://www.kiorapharma.com |
Full time employees 12 | Website https://www.kiorapharma.com | ||
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.